PO.BCS01.08 · 生物信息与计算

A general-purpose AI foundation model for spatial proteomics

海报缩略图:A general-purpose AI foundation model for spatial proteomics
编号 4163 展板 13 时间 4/21 09:00–12:00 区域 Section 3 主讲 Andrew Song, PhD
分会场 Digital Pathology 3
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Andrew H. Song1, Anurag Vaidya2, Muhammad Shaban1, Yuzhou Chang1, Huaying Qiu1, Yao Y. Yeo1, Guillaume Jaume1, Wenrui Wu1, Qin Ma3, Sizun Jiang1, Faisal Mahmood1

1Harvard Medical School, Boston, MA,2Massachusetts Institute of Technology, Cambridge, MA,3The Ohio State University, Columbus, OH

摘要 Abstract

Standard spatial proteomics (SP) pipelines for biomarker discovery have traditionally relied on cell segmentation followed by single-marker thresholding or rule-based mechanisms to assign cell phenotypes. However, this often suffers from a laborious process of manual annotations and neglects cell states characterized by the coordinated expression of multiple markers as a function of the cellular spatial organization. Moreover, converting the preprocessed cells to actionable biological insights on the cohort level is time-consuming due to its iterative nature of hypothesis generation and testing. We sought to build an AI foundation model trained on a large body of spatial proteomics datasets to address these challenges and further accelerate crucial spatial biology tasks in a platform-agnostic manner. We present KRONOS, a foundation model for spatial proteomics that operates directly on segmentation-free multiplex image patches. KRONOS extends the self-supervised learning recipe proven to be successful for several pathology foundation models to spatial proteomics, by employing a Vision Transformer architecture that can flexibly handle the variable number of protein markers and simultaneously encode the protein expression levels and the known biological properties of the protein. The training dataset for KRONOS consists of 47 million single-marker patches spanning 175 protein markers, 16 tissue types, eight fluorescence-based imaging platforms, across five different institutions. This diverse and large-scale dataset allows KRONOS to learn rich, low-dimensional image representations that effectively capture spatial protein expressions jointly across different markers. We evaluate KRONOS across a diverse range of downstream tasks, including cell phenotyping, tissue artifact detection, and patient stratification, and across diverse disease types such as lymphoma, renal cell carcinoma, and skin cancer. Across these tasks, KRONOS consistently outperforms other pathology (UNI) and spatial proteomics foundation model (CA-MAE) baselines, underscoring the importance of a domain-specific model trained on a large corpus of data. Specifically for cell phenotyping, we show that KRONOS is data-efficient and requires only a few cell annotations, addressing a major bottleneck in spatial proteomics where cell-level annotations are expensive to produce, slow to generate, and difficult to reuse across datasets. Furthermore, KRONOS allows “reverse image search” for identifying similar spatial patterns and biological concepts within and across patient cohorts, facilitating the discovery of clinically relevant tumor microenvironments and protein biomarkers.Together, these results position KRONOS as a general-purpose, foundation model for spatial proteomics that streamlines analysis, reduces annotation burden, and unlocks new opportunities for spatial biomarker discovery.
利益披露 Disclosure
A. H. Song, None.. A. Vaidya, None.. M. Shaban, None.. Y. Chang, None.. H. Qiu, None.. Y. Y. Yeo, None.. G. Jaume, None.. W. Wu, None.. Q. Ma, None. S. Jiang, Elucidate bio g., Board of Directors, non-salaried role), Stock, Stock Option. Roche ). Novartis ). F. Mahmood, Modella AI g., Board of Directors, non-salaried role), Stock, Stock Option. Danaher Advisory board.

在会议检索中打开